Clare Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Clare Miller has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Marie McIlroy
Androgens in Health and Disease Research Group, Academic Division of Endocrinology, Department of Medicine, Royal College of Surgeons in Ireland , Dublin D09 V2N0
2 shared publicationsMark Sherlock
Androgens in Health and Disease Research Group, Academic Division of Endocrinology, Department of Medicine, Royal College of Surgeons in Ireland , Dublin D09 V2N0
2 shared publications- Michael W. O'REilly
Androgens in Health and Disease Research Group, Academic Division of Endocrinology, Department of Medicine, Royal College of Surgeons in Ireland , Dublin D09 V2N0
2 shared publications Agnieszka Pazderska
Department of Endocrinology, St. James’s Hospital, Dublin, Ireland
1 shared publicationAmar Agha
Department of Endocrinology, Beaumont Hospital , Dublin D09 V2N0
1 shared publicationAmna Al‐Jabri
Department of Radiology and Molecular Imaging Sultan Qaboos University Seeb Oman
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Skeletal muscle is a critical site of disrupted lipid metabolism in male hypogonadism: an in vivo interventional study
Context: Male hypogonadism is associated with adverse cardiometabolic outcomes; however, tissue-specific metabolic mechanisms underlying this phenotype remain poorly characterized. Metabolomic profiling in hypogonadism to date has been confined to plasma, with limited insights into skeletal muscle. Objective: To characterize the impact of testosterone replacement therapy (TRT) and androgen deprivation therapy (ADT) on the plasma and skeletal muscle metabolome. Design: Parallel prospective interventional studies examined men initiating TRT for organic hypogonadism (n = 15) and ADT for prostate cancer (n = 15). Participants underwent metabolic phenotyping, plasma sampling, and vastus lateralis muscle biopsies pre- and postintervention (6 months TRT and 3 months ADT), with untargeted metabolomic profiling of both tissues at each timepoint. Results: Testosterone replacement therapy significantly increased serum testosterone (P < .001) and muscle mass (P < .05); ADT significantly reduced serum testosterone (P < .001) and muscle mass (P < .05) while simultaneously increasing fat mass (P < .05). Testosterone replacement therapy significantly altered a total of 118 plasma metabolites, reflecting predominant suppression of circulating lipid species, whereas ADT altered only 2. In skeletal muscle, TRT perturbed 89 metabolites and was characterized by expansion of intramuscular lipid species, while ADT altered 109 metabolites, with predominant depletion of intramuscular lipid classes. Following TRT, 8 lipid classes showed divergent responses between plasma and skeletal muscle. In skeletal muscle, 9 lipid classes responded differentially to TRT and ADT, including fatty acids, triacylglycerides, and ceramides. Conclusion: This study provides the first untargeted metabolomic characterization of skeletal muscle in response to androgen manipulation in humans. Distinct plasma and skeletal muscle responses demonstrate tissue-specific regulation that is incompletely captured by plasma profiling alone. These findings highlight skeletal muscle as a key site of androgen-sensitive metabolic regulation, providing evidence for tissue-specific lipid partitioning that may contribute to the cardiometabolic consequences of hypogonadism.
- 22 October 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessSkeletal muscle is a critical site of disrupted lipid metabolism in male hypogonadism: an in vivo interventional study
Context: Male hypogonadism is associated with adverse cardiometabolic outcomes; however, tissue-specific metabolic mechanisms underlying this phenotype remain poorly characterized. Metabolomic profiling in hypogonadism to date has been confined to plasma, with limited insights into skeletal muscle. Objective: To characterize the impact of testosterone replacement therapy (TRT) and androgen deprivation therapy (ADT) on the plasma and skeletal muscle metabolome. Design: Parallel prospective interventional studies examined men initiating TRT for organic hypogonadism (n = 15) and ADT for prostate cancer (n = 15). Participants underwent metabolic phenotyping, plasma sampling, and vastus lateralis muscle biopsies pre- and postintervention (6 months TRT and 3 months ADT), with untargeted metabolomic profiling of both tissues at each timepoint. Results: Testosterone replacement therapy significantly increased serum testosterone (P < .001) and muscle mass (P < .05); ADT significantly reduced serum testosterone (P < .001) and muscle mass (P < .05) while simultaneously increasing fat mass (P < .05). Testosterone replacement therapy significantly altered a total of 118 plasma metabolites, reflecting predominant suppression of circulating lipid species, whereas ADT altered only 2. In skeletal muscle, TRT perturbed 89 metabolites and was characterized by expansion of intramuscular lipid species, while ADT altered 109 metabolites, with predominant depletion of intramuscular lipid classes. Following TRT, 8 lipid classes showed divergent responses between plasma and skeletal muscle. In skeletal muscle, 9 lipid classes responded differentially to TRT and ADT, including fatty acids, triacylglycerides, and ceramides. Conclusion: This study provides the first untargeted metabolomic characterization of skeletal muscle in response to androgen manipulation in humans. Distinct plasma and skeletal muscle responses demonstrate tissue-specific regulation that is incompletely captured by plasma profiling alone. These findings highlight skeletal muscle as a key site of androgen-sensitive metabolic regulation, providing evidence for tissue-specific lipid partitioning that may contribute to the cardiometabolic consequences of hypogonadism.
- Open Access
- 30 September 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 191 (6) , R1-R17
Mechanisms in endocrinology: hypogonadism and metabolic health in men—novel insights into pathophysiology
Hypogonadism in men is associated with an adverse metabolic phenotype and increased mortality. Reciprocally, obesity and insulin resistance can suppress the hypothalamic–pituitary–gonadal axis in the absence of structural organic disease, further perpetuating a cycle of metabolic dysfunction and low testosterone. The mechanisms underpinning this bidirectional association are complex as hypogonadism is a heterogenous syndrome, and obesity is associated with metabolic perturbations in glucose and lipid metabolism even in the presence of normal testicular function. However, distinct molecular defects specific to testosterone deficiency have been identified in pathways relating to glucose and lipid metabolism in target metabolic depots such as adipose tissue and skeletal muscle. This review discusses the etiology and prevalence of metabolic disease in male hypogonadism, with a specific focus on both disease mechanisms and novel potential approaches to enhance our understanding.
- 30 September 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 191 (6) , R1-R17
Open AccessMechanisms in endocrinology: hypogonadism and metabolic health in men—novel insights into pathophysiology
Hypogonadism in men is associated with an adverse metabolic phenotype and increased mortality. Reciprocally, obesity and insulin resistance can suppress the hypothalamic–pituitary–gonadal axis in the absence of structural organic disease, further perpetuating a cycle of metabolic dysfunction and low testosterone. The mechanisms underpinning this bidirectional association are complex as hypogonadism is a heterogenous syndrome, and obesity is associated with metabolic perturbations in glucose and lipid metabolism even in the presence of normal testicular function. However, distinct molecular defects specific to testosterone deficiency have been identified in pathways relating to glucose and lipid metabolism in target metabolic depots such as adipose tissue and skeletal muscle. This review discusses the etiology and prevalence of metabolic disease in male hypogonadism, with a specific focus on both disease mechanisms and novel potential approaches to enhance our understanding.
- Open Access
- 3 April 2024
- Published by Wiley in Clinical Endocrinology
- Vol. 100 (6) , 585-592
Use of a dosimetry‐based RAI protocol for treatment of benign hyperthyroidism optimises response while minimising exposure to ionising radiation
Background: The optimal treatment strategy for radioiodine (RAI) treatment protocols for benign hyperthyroidism remains elusive. Although individualised activities are recommended in European Law, many centres continue to provide fixed activities. Our institution implemented a dosimetry protocol in 2016 following years of fixed dosing which facilitates the calculation of individualised activities based on thyroid volume and radioiodine uptake.Methods: This was a retrospective study comparing success rates using a dosimetry protocol targeting an absorbed dose of 150 Gy for Graves’ disease (GD) and 125 Gy for Toxic Multinodular Goiter (TMNG) with fixed dosing (200MBq for GD and 400MBq for TMNG) among 204 patients with hyperthyroidism. Success was defined as a non‐hyperthyroid state at 1 year for both disease states. Results were analysed for disease specific or patient specific modulators of response.Results: This study included 204 patients; 74% (n = 151) received fixed activities and 26% (n = 53) of activities administered were calculated using dosimetry. A dosimetry‐based protocol was successful in 80.5% of patients with GD and 100% of patients with TMNG. Differences in success rates and median activity administered between the fixed (204Mbq) and dosimetry (246MBq) cohort were not statistically significant (p = .64) however 44% of patients with GD and 70% of patients with TMNG received lower activities following treatment with dosimetry as opposed to fixed activities. Use of dosimetry resulted in successful treatment and reduced RAI exposure for 36% of patients with GD, 70% of patients with TMNG, and 44% of patients overall.Conclusion: This retrospective clinical study demonstrated that treatment with a dosimetry‐based protocol for TMNG and GD achieved comparable success rates to fixed protocols while reducing RAI exposure for over a third of patients with GD and most patients with TMNG. This study also highlighted that RAI can successfully treat hyperthyroidism for some patients with activities lower than commonplace in clinical practise. No patient or disease specific modulators of treatment response were established in this study; however, the data supports a future prospective trial which further scrutinises the individual patient factors governing treatment response to RAI.
- 3 April 2024
- Published by Wiley in Clinical Endocrinology
- Vol. 100 (6) , 585-592
Open AccessUse of a dosimetry‐based RAI protocol for treatment of benign hyperthyroidism optimises response while minimising exposure to ionising radiation
Background: The optimal treatment strategy for radioiodine (RAI) treatment protocols for benign hyperthyroidism remains elusive. Although individualised activities are recommended in European Law, many centres continue to provide fixed activities. Our institution implemented a dosimetry protocol in 2016 following years of fixed dosing which facilitates the calculation of individualised activities based on thyroid volume and radioiodine uptake.Methods: This was a retrospective study comparing success rates using a dosimetry protocol targeting an absorbed dose of 150 Gy for Graves’ disease (GD) and 125 Gy for Toxic Multinodular Goiter (TMNG) with fixed dosing (200MBq for GD and 400MBq for TMNG) among 204 patients with hyperthyroidism. Success was defined as a non‐hyperthyroid state at 1 year for both disease states. Results were analysed for disease specific or patient specific modulators of response.Results: This study included 204 patients; 74% (n = 151) received fixed activities and 26% (n = 53) of activities administered were calculated using dosimetry. A dosimetry‐based protocol was successful in 80.5% of patients with GD and 100% of patients with TMNG. Differences in success rates and median activity administered between the fixed (204Mbq) and dosimetry (246MBq) cohort were not statistically significant (p = .64) however 44% of patients with GD and 70% of patients with TMNG received lower activities following treatment with dosimetry as opposed to fixed activities. Use of dosimetry resulted in successful treatment and reduced RAI exposure for 36% of patients with GD, 70% of patients with TMNG, and 44% of patients overall.Conclusion: This retrospective clinical study demonstrated that treatment with a dosimetry‐based protocol for TMNG and GD achieved comparable success rates to fixed protocols while reducing RAI exposure for over a third of patients with GD and most patients with TMNG. This study also highlighted that RAI can successfully treat hyperthyroidism for some patients with activities lower than commonplace in clinical practise. No patient or disease specific modulators of treatment response were established in this study; however, the data supports a future prospective trial which further scrutinises the individual patient factors governing treatment response to RAI.
- Open Access
- 1 April 2023
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2023 (2)
Two cases of cardiomyopathy associated with phaeochromocytoma successfully managed with veno-arterial extracorporeal membrane oxygenation (V-A ECMO)
Summary Phaeochromocytoma, a rare neuroendocrine tumour of chromaffin cell origin, is characterised by catecholamine excess. Clinical presentation ranges from asymptomatic disease to life-threatening multiorgan dysfunction. Catecholamine-induced cardiomyopathy is a dreaded complication with high lethality. While there is lack of evidence-based guidelines for use of veno-arterial extracorporeal membrane oxygenation (V-A ECMO) in the management of this condition, limited to case reports and small case series, V-A ECMO has been reported as ‘bridge to recovery’ therapy, providing circulatory support in the initial period of stabilisation prior to surgery. We report on two patients presenting with catecholamine-induced cardiomyopathy and circulatory collapse who were successfully treated with V-A ECMO for 5 and 6 days, respectively, providing initial haemodynamic support. After stabilisation and introduction of alpha-blockade, both cases had favourable outcomes, with successful laparoscopic adrenalectomies on days 62 and 83 of admission, respectively. Our case reports provide further support for the use of V-A ECMO in the treatment of such gravely ill patients. Learning points Phaeochromocytoma should be considered in the diagnosis of patients presenting with acute cardiomyopathy. Management of catecholamine-induced cardiomyopathy is complex and requires multidisciplinary specialist input. Pre-operative management of phaeochromocytoma involves alpha-blockade; however, haemodynamic instability in the setting of cardiogenic shock can preclude alpha-blockade use. Veno-arterial extracorporeal membrane oxygenation is a life-saving intervention which may be considered in cases of acute catecholamine-induced cardiomyopathy and cardiogenic shock in order to provide the required haemodynamic support in the initial phase of treatment, enabling the administration of traditional pharmacological agents, including alpha-blockade. Abstract Summary Phaeochromocytoma, a rare neuroendocrine tumour of chromaffin cell origin, is characterised by catecholamine excess. Clinical presentation ranges from asymptomatic disease to life-threatening multiorgan dysfunction. Catecholamine-induced cardiomyopathy is a dreaded complication with high lethality. While there is lack of evidence-based guidelines for use of veno-arterial extracorporeal membrane oxygenation (V-A ECMO) in the management of this condition, limited to case reports and small case series, V-A ECMO has been reported as ‘bridge to recovery’ therapy, providing circulatory support in the initial period of stabilisation prior to surgery. We report on two patients presenting with catecholamine-induced cardiomyopathy and circulatory collapse who were successfully treated with V-A ECMO for 5 and 6 days, respectively, providing initial haemodynamic support. After stabilisation and introduction of alpha-blockade, both cases had favourable outcomes, with successful laparoscopic adrenalectomies on days 62 and 83 of admission, respectively. Our case reports provide further support for the use of V-A ECMO in the treatment of such gravely ill patients. Learning points Phaeochromocytoma should be considered in the diagnosis of patients presenting with acute cardiomyopathy. Management of catecholamine-induced cardiomyopathy is complex and requires multidisciplinary specialist input. Pre-operative management of phaeochromocytoma involves alpha-blockade; however, haemodynamic instability in the setting of cardiogenic shock can preclude alpha-blockade use. Veno-arterial extracorporeal membrane oxygenation is a life-saving intervention which may be considered in cases of acute catecholamine-induced cardiomyopathy and cardiogenic shock in order to provide the required haemodynamic support in the initial phase of treatment, enabling the administration of traditional pharmacological agents, including alpha-blockade.
- 1 April 2023
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2023 (2)
Open AccessTwo cases of cardiomyopathy associated with phaeochromocytoma successfully managed with veno-arterial extracorporeal membrane oxygenation (V-A ECMO)
Summary Phaeochromocytoma, a rare neuroendocrine tumour of chromaffin cell origin, is characterised by catecholamine excess. Clinical presentation ranges from asymptomatic disease to life-threatening multiorgan dysfunction. Catecholamine-induced cardiomyopathy is a dreaded complication with high lethality. While there is lack of evidence-based guidelines for use of veno-arterial extracorporeal membrane oxygenation (V-A ECMO) in the management of this condition, limited to case reports and small case series, V-A ECMO has been reported as ‘bridge to recovery’ therapy, providing circulatory support in the initial period of stabilisation prior to surgery. We report on two patients presenting with catecholamine-induced cardiomyopathy and circulatory collapse who were successfully treated with V-A ECMO for 5 and 6 days, respectively, providing initial haemodynamic support. After stabilisation and introduction of alpha-blockade, both cases had favourable outcomes, with successful laparoscopic adrenalectomies on days 62 and 83 of admission, respectively. Our case reports provide further support for the use of V-A ECMO in the treatment of such gravely ill patients. Learning points Phaeochromocytoma should be considered in the diagnosis of patients presenting with acute cardiomyopathy. Management of catecholamine-induced cardiomyopathy is complex and requires multidisciplinary specialist input. Pre-operative management of phaeochromocytoma involves alpha-blockade; however, haemodynamic instability in the setting of cardiogenic shock can preclude alpha-blockade use. Veno-arterial extracorporeal membrane oxygenation is a life-saving intervention which may be considered in cases of acute catecholamine-induced cardiomyopathy and cardiogenic shock in order to provide the required haemodynamic support in the initial phase of treatment, enabling the administration of traditional pharmacological agents, including alpha-blockade. Abstract Summary Phaeochromocytoma, a rare neuroendocrine tumour of chromaffin cell origin, is characterised by catecholamine excess. Clinical presentation ranges from asymptomatic disease to life-threatening multiorgan dysfunction. Catecholamine-induced cardiomyopathy is a dreaded complication with high lethality. While there is lack of evidence-based guidelines for use of veno-arterial extracorporeal membrane oxygenation (V-A ECMO) in the management of this condition, limited to case reports and small case series, V-A ECMO has been reported as ‘bridge to recovery’ therapy, providing circulatory support in the initial period of stabilisation prior to surgery. We report on two patients presenting with catecholamine-induced cardiomyopathy and circulatory collapse who were successfully treated with V-A ECMO for 5 and 6 days, respectively, providing initial haemodynamic support. After stabilisation and introduction of alpha-blockade, both cases had favourable outcomes, with successful laparoscopic adrenalectomies on days 62 and 83 of admission, respectively. Our case reports provide further support for the use of V-A ECMO in the treatment of such gravely ill patients. Learning points Phaeochromocytoma should be considered in the diagnosis of patients presenting with acute cardiomyopathy. Management of catecholamine-induced cardiomyopathy is complex and requires multidisciplinary specialist input. Pre-operative management of phaeochromocytoma involves alpha-blockade; however, haemodynamic instability in the setting of cardiogenic shock can preclude alpha-blockade use. Veno-arterial extracorporeal membrane oxygenation is a life-saving intervention which may be considered in cases of acute catecholamine-induced cardiomyopathy and cardiogenic shock in order to provide the required haemodynamic support in the initial phase of treatment, enabling the administration of traditional pharmacological agents, including alpha-blockade.
- Open Access
- 1 December 2021
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2021 (1)
Pheochromocytoma due to a novel SDHD variant presenting as unilateral visual loss
Summary: A 53-year-old female presented to a tertiary ophthalmology referral centre complaining of unilateral painless loss of vision. Subsequent assessment revealed malignant hypertension causing right-sided cystoid macular oedema. During the course of secondary hypertension workup, she was diagnosed with a 7.8 cm phaeochromocytoma which was resected. Testing for a panel of all predisposing phaeochromocytoma-causing variants using next-generation sequencing resulted in the diagnosis of a novel SDHD variant. Learning points: Screening for secondary causes of hypertension is indicated when there is evidence of hypertension-mediated end-organ damage (1). Testing for a predisposing variant should be considered in all patients with phaeochromocytoma or paraganglioma due to the high heritability rate and prevalence of somatic variants (2, 3, 4). Novel variants are commonly uncovered in the Succinate Dehydrogenase (SDH) subunit; proving pathogenicity is a complex, time-consuming process and one challenge of next-generation sequencing (3). SDHB immunohistochemistry as a tool for demonstrating pathogenicity is associated with reduced sensitivity when assessing SDHD variants (5, 6).
- 1 December 2021
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2021 (1)
Open AccessPheochromocytoma due to a novel SDHD variant presenting as unilateral visual loss
Summary: A 53-year-old female presented to a tertiary ophthalmology referral centre complaining of unilateral painless loss of vision. Subsequent assessment revealed malignant hypertension causing right-sided cystoid macular oedema. During the course of secondary hypertension workup, she was diagnosed with a 7.8 cm phaeochromocytoma which was resected. Testing for a panel of all predisposing phaeochromocytoma-causing variants using next-generation sequencing resulted in the diagnosis of a novel SDHD variant. Learning points: Screening for secondary causes of hypertension is indicated when there is evidence of hypertension-mediated end-organ damage (1). Testing for a predisposing variant should be considered in all patients with phaeochromocytoma or paraganglioma due to the high heritability rate and prevalence of somatic variants (2, 3, 4). Novel variants are commonly uncovered in the Succinate Dehydrogenase (SDH) subunit; proving pathogenicity is a complex, time-consuming process and one challenge of next-generation sequencing (3). SDHB immunohistochemistry as a tool for demonstrating pathogenicity is associated with reduced sensitivity when assessing SDHD variants (5, 6).